Altimmune, Inc.

NasdaqGM:ALT Stock Report

Market Cap: US$402.8m

Altimmune Management

Management criteria checks 2/4

Altimmune's CEO is Vipin Garg, appointed in Nov 2018, has a tenure of 7.08 years. total yearly compensation is $6.09M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $1.37M. The average tenure of the management team and the board of directors is 2.9 years and 6.3 years respectively.

Key information

Vipin Garg

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage10.40%
CEO tenure7.1yrs
CEO ownership0.3%
Management average tenure2.9yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates

Dec 22

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Mar 17

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Feb 28

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Feb 18

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Jan 15
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Altimmune Could Find A Partner For Its Phase 3 Exercise

Dec 30

Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 16

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 13

Regulatory And Clinical Catalysts Ahead For Altimmune

Oct 28

Consider Buying Potential Takeover Target Altimmune

Oct 02

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Sep 12
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27
We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

CEO Compensation Analysis

How has Vipin Garg's remuneration changed compared to Altimmune's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$84m

Jun 30 2025n/an/a

-US$88m

Mar 31 2025n/an/a

-US$90m

Dec 31 2024US$6mUS$633k

-US$95m

Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$5mUS$620k

-US$88m

Sep 30 2023n/an/a

-US$78m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$85m

Dec 31 2022US$3mUS$580k

-US$85m

Sep 30 2022n/an/a

-US$87m

Jun 30 2022n/an/a

-US$97m

Mar 31 2022n/an/a

-US$102m

Dec 31 2021US$3mUS$566k

-US$97m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$1mUS$514k

-US$49m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$815kUS$500k

-US$21m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$34m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$2mUS$44k

-US$42m

Compensation vs Market: Vipin's total compensation ($USD6.09M) is above average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.

CEO

Vipin Garg (67 yo)

7.1yrs
Tenure
US$6,090,462
Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Leadership Team

NamePositionTenureCompensationOwnership
Vipin Garg
President7.1yrsUS$6.09m0.34%
$ 1.4m
M. Roberts
Chief Scientific Officer13yrsUS$2.42m0.071%
$ 285.9k
Gregory Weaver
Chief Financial Officer1.1yrsno data0.022%
$ 89.1k
Andrew Shutterly
Principal Financial & Accounting Officer and Corporate Controller2.8yrsno data0.011%
$ 43.9k
Bertrand Georges
Chief Technology Officer8.6yrsno datano data
Tony Blandin
Vice President of Quality & Compliance Management3.8yrsno datano data
Robin Abrams
General Counsel & Chief Legal Officerno datano datano data
Raymond Jordt
Chief Business Officer2.9yrsUS$2.94m0.035%
$ 140.0k
Linda Richardson
Chief Commercial Officerless than a yearno datano data
Christophe Arbet-Engels
Chief Medical Officerless than a yearno datano data
2.9yrs
Average Tenure
62yo
Average Age

Experienced Management: ALT's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vipin Garg
President7.1yrsUS$6.09m0.34%
$ 1.4m
Mitchel Sayare
Independent Director15.7yrsUS$255.24k0.025%
$ 101.8k
John Gill
Independent Director21.3yrsUS$239.24k0.012%
$ 48.3k
Philip Hodges
Independent Director8.6yrsUS$251.24k0.0084%
$ 33.7k
Klaus Schafer
Independent Director8.6yrsUS$240.24k0.0088%
$ 35.4k
Catherine Sohn
Independent Director2.8yrsUS$233.99k0.00096%
$ 3.9k
Wayne Pisano
Independent Director7.3yrsUS$244.24k0.0081%
$ 32.8k
Jerome Durso
Independent Chairmanless than a yearno data0.012%
$ 48.3k
Diane Jorkasky
Independent Director5.6yrsUS$231.24k0%
$ 0
Rohit Loomba
Member of Mash Scientific Advisory Board3.4yrsno datano data
Mazen Noureddin
Member of Mash Scientific Advisory Board3.4yrsno datano data
Naga Chalasani
Member of Mash Scientific Advisory Board3.4yrsno datano data
6.3yrs
Average Tenure
72yo
Average Age

Experienced Board: ALT's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 01:29
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Altimmune, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Jonathan WollebenCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI